1. Geographic heterogeneity in the prevalence of human papillomavirus in head and neck cancer.
- Author
-
Anantharaman D, Abedi-Ardekani B, Beachler DC, Gheit T, Olshan AF, Wisniewski K, Wunsch-Filho V, Toporcov TN, Tajara EH, Levi JE, Moyses RA, Boccia S, Cadoni G, Rindi G, Ahrens W, Merletti F, Conway DI, Wright S, Carreira C, Renard H, Chopard P, McKay-Chopin S, Scelo G, Tommasino M, Brennan P, and D'Souza G
- Subjects
- Biomarkers, Tumor genetics, Brazil, Cyclin-Dependent Kinase Inhibitor p16 genetics, Europe, Gene Expression Regulation, Neoplastic, Head and Neck Neoplasms genetics, Head and Neck Neoplasms pathology, Head and Neck Neoplasms virology, Human papillomavirus 16 isolation & purification, Human papillomavirus 16 pathogenicity, Humans, United States, Biomarkers, Tumor biosynthesis, Cyclin-Dependent Kinase Inhibitor p16 biosynthesis, Head and Neck Neoplasms epidemiology, Human papillomavirus 16 genetics
- Abstract
Human papillomavirus (HPV) causes oropharyngeal squamous cell carcinoma (OPSCC), although strongly divergent results have been reported regarding the prevalence of HPV16 in different countries, whether this represents important differences in etiology remains unclear. Applying rigorous protocols for sample processing, we centrally evaluated 1,420 head and neck tumors (533 oropharynx, 395 oral cavity and 482 larynx) from studies conducted in the US, Europe and Brazil for mucosal HPV DNA and p16
INK4a expression to evaluate regional heterogeneity in the proportion of HPV16-associated OPSCC and other head and neck cancer, and to assess covariates associated with the risk of HPV16-positive OPSCC. While majority of OPSCC in the US (60%) were HPV16-positive, this proportion was 31% in Europe and only 4% in Brazil (pā<ā0.01). Similar differences were observed for other head and neck tumors, ranging from 7% in the US and 5% in Europe, to 0% in South America. The odds of HPV16-positive OPSCC declined with increasing pack years of smoking (OR: 0.75; 95% CI: 0.64-0.87) and drink years of alcohol use (OR: 0.64; 95% CI: 0.54-0.76). These results suggest that while the contribution of HPV16 is substantial for the oropharynx, it remains limited for oral cavity and laryngeal cancers., (© 2017 IARC/WHO.)- Published
- 2017
- Full Text
- View/download PDF